New fellowship to strengthen commercial research opportunities Dr Cindy Shu will have a key role in building commercial capabilities Research Lab to improve therapies for osteoarthritis
“Our program expects researchers to return to their home institution so this ensures we embed high-level, industry-ready experience in the research sector,” he said. Cindy has welcomed the chance to be involved in the program. “This opportunity will help me pursue my research interest in osteoarthritis, and will ensure research translation, rather than having valuable data remain solely in the research- publication loop,” she said. “I’m very excited to be collaborating with Regeneus and welcome the chance to be part of their mentoring program which will guide me through the pathway between bench and bedside.” Regeneus has also announced an exciting research collaboration with Professor Chris Little and the Raymond Purves Bone and Joint
at the Kolling after receiving a fellowship from the Researcher Exchange and Development within Industry (REDI) program. The program provides financial support to medical technology and pharmaceutical companies to bring the best talent in-house to work on priority medical research projects. Cindy is one of just two researchers in NSW to receive the fellowship, and will now work within Regeneus, a regenerative medicine company to progress clinical trials for osteoarthritis treatments. MTPConnect Managing Director and CEO Dr Dan Grant said supporting researchers to move seamlessly between research and industry is critical for the growth of Australia’s medical technology and pharmaceutical sector.
The study will further explore the disease modifying effects of Progenza™ and assess its effect in modulating the inflammatory and immune responses in a pre- clinical mode of post-traumatic osteoarthritis. Regeneus and Professor Little have worked together over a number years, previously conducting equine animal studies. CEO Karolis Rosickas said we’re very pleased to be working with Professor Little and his team. “We look forward to working together on this important study which will support our Progenza™ clinical program, where we will shortly commence a Phase 2 trial in Japan with our partner Kyocera and are currently conducting preparatory work for a US Phase 2 study.”
Dr Cindy Shu
Professor Chris Little
4
KOLLINGNEWS | SEPTEMBER 2021
Made with FlippingBook - professional solution for displaying marketing and sales documents online